PATENT CLAIM ANALYSIS

Application Number: 15875479
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["424", "190100"]

Abstract:
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of  Borrelia  genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Claim (Index 39):
The combination vaccine of  claim 37  wherein the second vaccine composition is a vaccine selected from the group consisting of: a tick-borne encephalitis vaccine, a Japanese encephalitis vaccine, and a Rocky Mountain Spotted Fever vaccine.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.69492
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14078390', '14078367', '13939759', '13107796', '13107787']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8650999743631838
- 35 USC 102 Novelty (BERT): 0.6363826226160599
- Combined Prediction Score: 0.8422282391884713
- Mean Citation Score: 696.765474
- Max Citation Score: 729.3804
- Similarity Product: 534.1442532251358

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test